Can a dopamine-blocking drug safely control tourette syndrome over years?
Disease control
Ongoing
This trial investigates the long-term safety of ecopipam, a drug that blocks dopamine D1 and D5 receptors, in children, adolescents, and adults with Tourette syndrome. Participants who completed a prior study may enroll and receive ecopipam for up to 24 weeks or longer. The main …
Phase: PHASE3 • Sponsor: Emalex Biosciences Inc. • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC